A PHASE IIA STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND EFFICACY OF APG-115 AS A SINGLE AGENT OR IN COMBINATION WITH APG-2575 IN SUBJECTS WITH RELAPSED/REFRACTORY T-CELL PROLYMPHOCYTIC LEUKEMIA (R/R T-PLL)
MD Anderson Study Status
This is a multi-center, open-label, phase IIa study to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL. The study consists of two parts. A total of 24-36 T-PLL patients will be enrolled.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.